Linda Malkas, Ph.D., deputy director of basic research and the M.T. & B.A. Ahmadinia Professor in Molecular Oncology, has been appointed to the governing board of the California Institute for Regenerative Medicine (CIRM).
As a board member, Dr. Malkas will be charged with adopting scientific, medical, ethical and intellectual property policies, making decisions on grant loans and awards, and overseeing the general operations of CIRM.
CIRM’s 29-member board is comprised of individuals who are leading innovative medical research; who understand the critical path for developing medical treatments and directing the approval process through the Food & Drug Administration (FDA); and, who can advocate for patients suffering from chronic diseases and injuries.
“Dr. Malkas is extraordinarily well-qualified for the post,” says California Treasurer John Chiang, who made the appointment. “She has a stellar career in both research and administration, promoting and advancing research in women’s health with a particular focus on breast cancer.” Chiang cited Dr. Malkas’ research expertise in the areas of human cell DNA replication and repair, in biomarker and therapeutic discovery and development.You can watch a brief video on her research here.
“We are extremely happy to welcome Dr. Malkas to the Board,” says Jonathan Thomas, Ph.D., J.D., chair of the CIRM board. “Not only has she demonstrated expertise and leadership in science and academia, but the collaborative approach she has shown throughout her career make her an excellent addition to CIRM.”
Dr. Malkas served for five years on a National Cancer Institute (NCI) subcommittee reviewing cancer center designations. She chaired several NCI study panels and recently took on an advisory role on drug approval policy with the FDA.
“The research and technologies developed through this agency have benefited the health of not only Californians but the nation and world,” says Dr. Malkin, who is a professor of molecular and cellular biology at the Beckman Research Institute (BRI) and the joint head of our Molecular Oncology Program. “I am excited to see what the future holds for the work of this agency.”
CIRM was created in 2004 after 59 percent of California voters approved Proposition 71, the California Stem Cell Research and Cures Initiative, which funds CIRM’s stem cell research.